Incyte Earnings Beat, Revenue Misses In Q1 By Investing.com

0
15

© Reuters. Incyte Earnings Beat, Revenue Misses In Q1

Investing.com – Incyte (NASDAQ:) reported on Tuesday first quarter that beat analysts’ forecasts and revenue that fell short of expectations.

Incyte announced earnings per share of $0.67 on revenue of $604.7M. Analysts polled by Investing.com anticipated EPS of $0.4617 on revenue of $662.22M.

Incyte shares are up 31% from the beginning of the year, still down 22.48% from its 52 week high of $110.32 set on July 7, 2020. They are outperforming the S&P 500 which is up 11.62% from the start of the year.

Incyte follows other major Healthcare sector earnings this month

Incyte’s report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.

Pfizer had beat expectations on Tuesday with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7773 on revenue of $13.67B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.